Free Trial
NASDAQ:PACB

Pacific Biosciences of California (PACB) Stock Price, News & Analysis

$1.87
-0.05 (-2.60%)
(As of 01:52 PM ET)
Today's Range
$1.86
$1.95
50-Day Range
$1.36
$4.24
52-Week Range
$1.25
$14.55
Volume
2.43 million shs
Average Volume
10.20 million shs
Market Capitalization
$509.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.59

Pacific Biosciences of California MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.53 Rating Score
Upside/​Downside
246.9% Upside
$6.59 Price Target
Short Interest
Bearish
19.39% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.38mentions of Pacific Biosciences of California in the last 14 days
Based on 17 Articles This Week
Insider Trading
Acquiring Shares
$176,000 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.93) to ($0.77) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.73 out of 5 stars

Medical Sector

421st out of 921 stocks

Analytical Instruments Industry

14th out of 27 stocks

PACB stock logo

About Pacific Biosciences of California Stock (NASDAQ:PACB)

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

PACB Stock Price History

PACB Stock News Headlines

Mid-Week Wednesday's Most Active Buys
See More Headlines
Receive PACB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pacific Biosciences of California and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/09/2024
Today
5/21/2024
Next Earnings (Estimated)
8/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:PACB
CUSIP
69404D10
Employees
796
Year Founded
2004

Price Target and Rating

Average Stock Price Target
$6.59
High Stock Price Target
$15.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+246.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.53
Research Coverage
15 Analysts

Profitability

Net Income
$-306,730,000.00
Net Margins
-148.13%
Pretax Margin
-153.83%

Debt

Sales & Book Value

Annual Sales
$200.43 million
Book Value
$2.62 per share

Miscellaneous

Free Float
268,543,000
Market Cap
$517.48 million
Optionable
Optionable
Beta
1.99

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Christian O. Henry M.B.A. (Age 56)
    President, CEO & Director
    Comp: $1.1M
  • Ms. Susan G. KimMs. Susan G. Kim (Age 47)
    Chief Financial Officer
    Comp: $564.87k
  • Mr. Mark Van Oene (Age 51)
    Chief Operating Officer
    Comp: $772.11k
  • Mr. Jeff Eidel (Age 47)
    Chief Commercial Officer
    Comp: $435.62k
  • Dr. Stephen Turner Ph.D. (Age 56)
    Co-Founder
    Comp: $341.25k
  • Ms. Michele Farmer CPA (Age 44)
    VP & Chief Accounting Officer
  • Trevin Rard
    Head of Investor Relations
  • Dr. Brett Atkins J.D.
    Ph.D., General Counsel & Corporate Secretary
  • Ms. Natalie Welch
    Chief People Officer
  • Dr. Denis Zaccarin Ph.D. (Age 58)
    Senior Vice President of Research & Development
    Comp: $510.77k

PACB Stock Analysis - Frequently Asked Questions

Should I buy or sell Pacific Biosciences of California stock right now?

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last year. There are currently 7 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PACB shares.
View PACB analyst ratings
or view top-rated stocks.

What is Pacific Biosciences of California's stock price target for 2024?

15 analysts have issued 12 month price objectives for Pacific Biosciences of California's stock. Their PACB share price targets range from $2.00 to $15.00. On average, they predict the company's stock price to reach $6.59 in the next year. This suggests a possible upside of 246.9% from the stock's current price.
View analysts price targets for PACB
or view top-rated stocks among Wall Street analysts.

How have PACB shares performed in 2024?

Pacific Biosciences of California's stock was trading at $9.81 on January 1st, 2024. Since then, PACB stock has decreased by 80.6% and is now trading at $1.90.
View the best growth stocks for 2024 here
.

When is Pacific Biosciences of California's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024.
View our PACB earnings forecast
.

How were Pacific Biosciences of California's earnings last quarter?

Pacific Biosciences of California, Inc. (NASDAQ:PACB) released its quarterly earnings results on Thursday, May, 9th. The biotechnology company reported ($0.26) EPS for the quarter, hitting the consensus estimate of ($0.26). The biotechnology company earned $38.81 million during the quarter, compared to analysts' expectations of $38.78 million. Pacific Biosciences of California had a negative trailing twelve-month return on equity of 40.26% and a negative net margin of 148.13%.

What guidance has Pacific Biosciences of California issued on next quarter's earnings?

Pacific Biosciences of California issued an update on its first quarter 2024 earnings guidance on Tuesday, April, 16th. The company provided EPS guidance of for the period. The company issued revenue guidance of $38.8 million-$38.8 million, compared to the consensus revenue estimate of $50.3 million.

What is Christian Henry's approval rating as Pacific Biosciences of California's CEO?

2 employees have rated Pacific Biosciences of California Chief Executive Officer Christian Henry on Glassdoor.com. Christian Henry has an approval rating of 100% among the company's employees. This puts Christian Henry in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Pacific Biosciences of California own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacific Biosciences of California investors own include Pfizer (PFE), Gilead Sciences (GILD), Illumina (ILMN), Novavax (NVAX), Advanced Micro Devices (AMD), AT&T (T), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Invitae (NVTA) and Tesla (TSLA).

Who are Pacific Biosciences of California's major shareholders?

Pacific Biosciences of California's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.77%), Sumitomo Mitsui Trust Holdings Inc. (4.79%), Nikko Asset Management Americas Inc. (4.71%), Edmond DE Rothschild Holding S.A. (3.86%), Jackson Square Partners LLC (2.64%) and Bellevue Group AG (1.69%). Insiders that own company stock include Christian O Henry, David W Meline, Kathy Ordonez, Michele Farmer, Oene Mark Van, Peter Fromen, Susan G Kim and William W Ericson.
View institutional ownership trends
.

How do I buy shares of Pacific Biosciences of California?

Shares of PACB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Pacific Biosciences of California have any subsidiaries?
The following companies are subsidiares of Pacific Biosciences of California: Circulomics, Omniome, PacBio Singapore PTE Limited, Pacific Biosciences (Shanghai) Co. Ltd., Pacific Biosciences Canada Limited, Pacific Biosciences Germany GmbH, Pacific Biosciences International LLC, Pacific Biosciences Japan GK, and Pacific Biosciences UK Limited.
Read More
This page (NASDAQ:PACB) was last updated on 5/21/2024 by MarketBeat.com Staff

From Our Partners